Syndax Pharmaceuticals Inc Annual Report Overview (Fiscal Year Ended December 31, 2025)

This overview distills key information from Syndax Pharmaceuticals Inc.'s annual report for the fiscal year ended December 31, 2025. It offers investors crucial insights into the company's operations, financial performance, strategic direction, and associated risks.

Company Profile and Standing (Business Overview)

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for cancer and fibrotic diseases. As a "well-known seasoned issuer" and a "large accelerated filer," Syndax demonstrates a strong market presence and consistently provides timely, transparent financial reporting to the SEC.

As of June 30, 2025, the market valued the company's common stock held by non-affiliates at approximately $799.2 million, with a stock price of $9.36 per share. By February 23, 2026, Syndax had approximately 88.2 million shares of common stock outstanding.

Financial Performance Highlights (Fiscal Year Ended December 31, 2025)

Syndax's financial results underscore its significant investment in research and development, alongside growing revenue streams from collaborations as its product candidates advance.

• Total Revenue:
  • 2025: $65.8 million, primarily from collaboration and milestone payments.
  • 2024: $42.1 million.
  • Breakdown for 2025:
    • Collaboration Revenue: $50.5 million, largely from the partnership with Incyte Corporation for axatilimab.
    • Milestone Revenue: $15.3 million, achieved upon reaching specific development goals for pipeline candidates.
    • Net Product Revenues: $0.0 million, as neither Revumenib nor Axatilimab had received commercial approval by year-end 2025.
• Operating Expenses:
  • Research and Development (R&D) Expenses: These increased significantly as clinical trials progressed.
    • 2025: $195.2 million.
    • 2024: $168.7 million.
  • Selling, General, and Administrative (SG&A) Expenses: These also rose in anticipation of potential commercialization.
    • 2025: $78.5 million.
    • 2024: $62.3 million.
• Net Loss: As expected for a clinical-stage biotech, the company reported a net loss due to substantial R&D investments.
  • 2025: $(208.9) million.
  • 2024: $(185.6) million.

Management's Discussion and Analysis (MD&A) Highlights

Management's discussion highlights the company's progress in advancing its clinical pipeline and effectively managing financial resources to support these efforts. Total revenue grew from $42.1 million in 2024 to $65.8 million in 2025. This increase primarily stemmed from higher collaboration revenue from the Incyte partnership for axatilimab, reflecting the achievement of development milestones and ongoing activities. The absence of net product revenues emphasizes the company's current focus on clinical development.

Operating expenses saw a notable increase. R&D expenses rose from $168.7 million in 2024 to $195.2 million in 2025, driven by significant investment in the pivotal Phase 3 AUGMENT-101 trial for Revumenib and ongoing clinical development activities for Axatilimab, including pre-commercialization manufacturing and regulatory submission costs. SG&A expenses also increased from $62.3 million to $78.5 million, primarily due to higher personnel costs, professional fees, and pre-commercialization activities in anticipation of potential regulatory approvals and product launches for both lead candidates.

The resulting net loss of $(208.9) million in 2025, compared to $(185.6) million in 2024, reflects Syndax's continued heavy investment in research and development. This level of investment is typical for a biopharmaceutical company in the clinical stage. Management continues to prioritize efficient capital allocation to advance its most promising programs toward commercialization.

Financial Health (Debt, Cash, Liquidity)

As of December 31, 2025, Syndax held $345.0 million in cash, cash equivalents, and marketable securities. The company projects this capital will fund operations into late 2027, based on current spending rates and planned expenditures, including ongoing clinical trials and pre-commercialization activities. Existing cash reserves and strategic capital-raising activities primarily support Syndax's strong liquidity position.

From 2023 to 2025, Syndax strategically raised capital through various offerings, including direct placements and at-the-market (ATM) stock offerings. While these activities provided essential funding for drug development and extended the cash runway, they resulted in some dilution of existing shareholder value. The company maintains no significant long-term debt, relying primarily on equity financing and collaboration revenues to fund its operations. Management continuously monitors capital needs and explores various financing options to ensure sufficient liquidity for its strategic objectives.

Future Outlook (Guidance, Strategy)

Syndax's core strategy centers on advancing its two lead product candidates, Revumenib and Axatilimab, through clinical development, regulatory approval, and eventual commercialization.

• Revumenib: This oral, small molecule menin inhibitor treats relapsed/refractory acute leukemias, particularly those with KMT2A rearrangements or NPM1 mutations.
  • Clinical Status: The company completed enrollment for its pivotal Phase 3 AUGMENT-101 trial in 2025, with top-line data anticipated in mid-2026.
  • Regulatory Pathway: Syndax plans to submit a New Drug Application (NDA) to the FDA for Revumenib in late 2026, contingent on positive trial results. An NDA is a formal request for FDA approval to market a new drug.
• Axatilimab: This monoclonal antibody targets the CSF-1R pathway and treats chronic graft-versus-host disease (cGvHD) and other fibrotic diseases.
  • Clinical Status: Syndax submitted an NDA for axatilimab in cGvHD to the FDA in early 2025, and the FDA accepted it for review. A PDUFA (Prescription Drug User Fee Act) target action date is set for early 2026, indicating when the FDA expects to complete its review.
  • Partnership: Syndax develops and commercializes Axatilimab globally in collaboration with Incyte Corporation. Syndax is eligible for significant milestone payments and royalties on future sales.
• Partnerships & Collaborations: Beyond Incyte, Syndax holds strategic license agreements with UCB Biopharma and Vitae Pharmaceuticals (an AbbVie company) for earlier-stage programs. These collaborations offer potential for future milestone and royalty payments, proving critical for expanding the pipeline and sharing development costs and risks. The company continues to evaluate potential new partnerships to further expand its pipeline and therapeutic reach.

Competitive Landscape (Competitive Position)

The biopharmaceutical industry, especially in oncology and fibrotic diseases, is highly competitive. It features rapid technological change, intense research and development, and a strong emphasis on intellectual property. Syndax faces significant competition from both large, established pharmaceutical companies and smaller, emerging biotechnology firms developing or already commercializing treatments for acute leukemias and chronic graft-versus-host disease (cGvHD).

Key competitive factors include a product candidate's efficacy, safety, mechanism of action, convenience of dosing, price, and intellectual property protection. Syndax's strategy involves developing therapies with novel mechanisms of action, such as menin inhibition for Revumenib and CSF-1R inhibition for Axatilimab. These aim to offer differentiated clinical benefits or address unmet medical needs. The company believes its lead product candidates, if approved, could offer significant advantages over existing treatments. However, their ultimate competitive position will depend on clinical outcomes, regulatory success, market acceptance, and the emergence of new therapies.

Key Risks for Investors

Investing in Syndax Pharmaceuticals, like any biopharmaceutical company, carries significant risks:

• Clinical Trial Outcomes: The success of Revumenib and Axatilimab depends heavily on positive results from ongoing and future clinical trials. There is no guarantee that trials will meet primary endpoints, demonstrate sufficient efficacy or safety, or that researchers can replicate results. Failure in pivotal trials would severely impact the company's valuation and future prospects.
• Regulatory Approval: Obtaining regulatory approval from agencies like the FDA and EMA is a complex, lengthy, and uncertain process. Delays, requests for additional data, or outright rejections could significantly postpone or prevent commercialization, even with positive clinical data.
• Competition: The therapeutic areas Syndax targets are highly competitive. Other companies develop or have already commercialized treatments for acute leukemias and cGvHD. Revumenib and Axatilimab may not achieve market acceptance or compete effectively against existing or future therapies.
• Funding Requirements: Developing new drugs is capital-intensive. While Syndax maintains a solid cash position, it may need to raise additional capital in the future. This could involve further equity offerings, potentially diluting existing shareholders, or debt, which would increase financial leverage.
• Intellectual Property: Syndax's success relies on its ability to obtain, maintain, and enforce patent protection for its product candidates. Challenges to its patents or the inability to secure adequate protection could allow competitors to market similar products, eroding market share and profitability.
• Manufacturing and Supply Chain: The company relies on third-party manufacturers for its drug candidates. Any disruptions in the supply chain, manufacturing delays, or quality control issues could impact clinical trials or commercial launch.
• Market Acceptance and Commercialization: Even if approved, there is no guarantee that physicians and patients will widely adopt Revumenib or Axatilimab. Factors such as pricing, reimbursement, and perceived benefits relative to alternatives will influence commercial success.
• Customer Concentration: In 2025, a significant portion of Syndax's collaboration revenue came from a limited number of partners (four key partners, down from five in 2024). The loss or significant reduction of business from any of these partners could materially impact revenue.